Posted by Michael Wonder on 28 Aug 2018
NICE says ‘no’ to Gilead's Yescarta in draft guidelines
28 August 2018 - NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by NICE.
The drug as just won EU approval having been shown to be clinically effective in treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma in people who have had two or more systemic therapies.
Along with Novartis’ Kymriah (tisagenlecleucel), it is the first CAR-T therapy – a process by which T cells are drawn from a patient's blood and reprogrammed in the lab to create T cells that are genetically coded to hunt the patient's cancer cells -to be cleared for use in the region.
